Table of Contents
UPDATE: To Watch the Replay of Kyle’s Option Rocket Webinar
>>> Click Here and Register <<<
You’ll receive your replay link in a few minutes.
For those of you that missed it, here is my Lesson on the Basics of Options, which I held live on Facebook. Be sure to check it out, as there is incredibly valuable information in that presentation.
I’m holding a really big event coming up in a couple weeks that I want to bring to your attention.
Details on that event are located right here.
The portfolio continues to grind and I’m looking for more spots to take action.
I’ll have more to come soon!
Just a reminder, charts and targets are updated every Monday morning!
—– Related —–
FREE DOWNLOAD
Kyle Dennis FREE EBOOK “The $2.9 Million Biotech Trader Playbook”
This book has helped thousands of other traders learn the basics of biotech, and how to easily spot winning trades.
Whether you are new trader or a 30-year veteran, this book will help you find stocks that are primed to make parabolic moves. These strategies are Kyle’s secret weapons that have help him net over $3 Million in profits…and they are all yours for free.
This is normally $97.00, but it’s yours FREE!
Catalyst Swing names (1 – 4 week holds) I am watching…
Calithera Biosciences (CALA)
Catalyst Dates: Phase 1/2 data due out at ASCO June 3rd with abstracts released May 16th
Buy Zone: $6.00 to $6.50
Profit Zone: $7.00 or higher
Stop Zone: $5.75 or below
Stemline Therapeutics (STML)
Catalyst Dates: Phase 2 and Phase 1 Data due out at ASCO June 2nd and 4thwith abstracts released May 16.
Buy Zone: $17.00 to $18.00
Profit Zone: $20.00 or higher
Stop Zone: $16.00 or below
Rocket Pharmaceuticals (RCKT)
Catalyst Dates: Phase 1/2 update for gene therapy to be presented May 18th
Buy Zone: $16.50 to $17.50
Profit Zone: $19.00 or higher
Stop Zone: $16.00 or below
Marinus Pharmaceuticals (MRNS)
Catalyst Dates: Phase 2 data due out in the third quarter. Two other Phase 2 datas due out in the fourth quarter.
Buy Zone: $4.25 to $4.75
Profit Zone: $6.00 or higher
Stop Zone: $4.00 or below
GTx, Inc (GTXI)
Catalyst Dates: Updated date to be presented May 18 at the AUA Meeting
Buy Zone: $16.50 to $17.50
Profit Zone: $19.00 or higher
Stop Zone: $16.00 or below
NewLink Genetics (NLNK)
Catalyst Dates: Phase 2 Pancreatic Cancer Data due out June 3 (May 16abstracts come online)
Buy Zone: $4.50 to $4.80
Profit Zone: $6.00 or higher
Stop Zone: $4.00 or below
ARMO Biosciences (ARMO)
Catalyst Dates: Two Phase 2 data updates due June 2nd (abstracts onlineMay 16)
Buy Zone: $25.00 to $27.00
Profit Zone: $30.00 or higher
Stop Zone: $24.50 or below
Cytokinetics Incorporated (CYTK)
Catalyst Dates: Phase 2 data due out June 16
Buy Zone: $8.00 to $8.50
Profit Zone: $10.00 or higher
Stop Zone: $7.40 or below
Zogenix (ZGNX)
Catalyst Dates: Phase 3 data due late second quarter (likely June)
Buy Zone: $39.50 to $40.50
Profit Zone: $45.00 or higher
Stop Zone: $37.50 or below
Rexahn Pharmaceuticals (RNN)
Catalyst Dates: Phase 2 data due out May 16 and June 2
Buy Zone: $1.70 to $1.85
Profit Zone: $2.40 or higher
Stop Zone: $1.40 or below
Dermira (DERM)
Catalyst Dates: FDA Approval date of June 30th
Buy Zone: $8.50 to $9.00
Profit Zone: $10.00 or higher
Stop Zone: $8.00 or below
MEI Pharma (MEIP)
Catalyst Dates: Two Phase 1 and one Phase 2 data due in the second quarter (likely around early June)
Buy Zone: $2.00 to $2.20
Profit Zone: $2.80 or higher
Stop Zone: $1.80 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Phase 2 data in July
Buy Zone: $26.50 to $28.50
Profit Zone: $33.00 or higher
Stop Zone: $25.00 or below
Pain Therapeutics (PTIE)
Catalyst Dates: Advisory Committee Meeting June 26th and FDA approval date of August 7th
Buy Zone: $7.50 to $8.25
Profit Zone: $9.50 or higher
Stop Zone: $7.00 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $4.50 to $5.00
Profit Zone: $7.00 or higher
Stop Zone: $4.00 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.